Music Therapy and Robotics Team Up to Protect Aging Brains
A 210-person trial tests whether 5-month music therapy programs — and robotic assistants — can slow cognitive decline in older adults.
Summary
The MusiCare trial enrolled 210 older adults, ranging from cognitively healthy to those with mild-to-moderate impairment, to test whether structured music therapy delivered in individual or group formats could preserve cognitive function and wellbeing. Running for five months, the study compared one-to-one sessions, small-group, and large-group music therapy against standard care. A novel component examined whether robotic assistance technologies could enhance delivery and outcomes. Researchers tracked psychological measures including cognitive function, quality of life, and social engagement, alongside physiological markers like hormonal levels, cardiovascular responses, and brain activity. The trial, now completed, aimed to establish which music therapy format works best for which level of cognitive decline — providing evidence to support social prescribing and non-pharmacological dementia prevention strategies.
Detailed Summary
As global dementia rates climb, health systems urgently need low-cost, scalable interventions that preserve cognitive function and quality of life. Pharmacological options remain limited, and policy-makers have increasingly turned to social prescribing — recommending non-drug activities such as music, exercise, and social engagement — as part of preventive care strategies. Music therapy has shown early promise, but rigorous clinical evidence is sparse.
The MusiCare trial, sponsored by Middlesex University, enrolled 210 older adults across three sub-studies to test the cognitive and psychosocial benefits of structured music therapy. Participants ranged from cognitively healthy individuals to those experiencing mild-to-moderate impairment in care home settings. Interventions lasted five months and were delivered in three formats: one-to-one, small-group, and large-group sessions. A control group received standard care, with music therapy offered afterward.
A particularly innovative dimension of the study was the integration of robotic assistance technologies into music therapy delivery. Researchers investigated whether these tools could enhance participant engagement, support therapists, and improve the scalability of music-based interventions for community health services.
Outcomes were measured across both psychological and physiological domains. Cognitive function, wellbeing, and quality of life were assessed before and after the intervention, alongside hormonal, cardiovascular, and brain activity measures — providing a comprehensive picture of music therapy's biological and psychosocial impact.
The trial was completed in May 2024. Results are anticipated to help clinicians and care planners match specific music therapy formats to patients based on their level of cognitive decline. If findings confirm meaningful benefits, music therapy could be formally integrated into dementia prevention programs worldwide. Key caveats include the non-pharmacological Phase NA design, meaning blinding is inherently limited, and the summary here is based on the abstract only.
Key Findings
- Five-month music therapy interventions were tested across healthy and cognitively impaired older adults in a 210-person trial.
- Three delivery formats — one-to-one, small-group, and large-group — were compared to identify the best fit for each cognitive level.
- Robotic assistance technologies were evaluated as a novel tool to enhance music therapy delivery and scalability.
- Both psychological and physiological outcomes were measured, including brain activity, hormones, and cardiovascular markers.
- Completed in 2024, results may support music therapy as a formal component of dementia prevention and social prescribing programs.
Methodology
A three-sub-study, controlled trial enrolling 210 older adults comparing 5-month music therapy formats against standard care, with control participants receiving therapy after the study period. Outcome measures spanned psychological assessments and physiological biomarkers including neurological, hormonal, and cardiovascular indicators. Robotic assistance technology was evaluated as an adjunct intervention in a subset of participants.
Study Limitations
This summary is based on the abstract only, as the full trial results have not been reviewed. As a non-pharmacological behavioral trial, blinding of participants is not feasible, introducing potential performance and expectation bias. Generalizability may be limited by the care home and university-affiliated recruitment setting.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.